Our Mission is to Address Unmet Medical Need in IBD Patients
with a Novel Therapy, Differentiated through upstream modulation
Our program is a clinical stage, oral small molecule drug candidate targeting upstream of TNFa, IL-23, a4b7, S1P, TL1A & JAKi biology, converging on validated pathways that enables combination with approved blockbuster drugs allowing broader anti-inflammatory effects.
IBD imposes a lifelong, escalating burden: roughly half of patients never reach remission on any current advanced therapy, and one third of initial responders lose response over time
7M
Global IBD Patients
Growing market with significant unmet need
>$15B
US Market (Sales)
$7B Ulcerative Colitis + $9B Crohn's Disease
8%
Projected CAGR
Growth projected through 2030
US Patient Population
Inflammatory Bowel Disease comprises two principal indications
| Indication | US Patients |
|---|---|
| Crohn's Disease (CD) | 1.0 Million |
| Ulcerative Colitis (UC) | 1.3 Million |
Treatment Gap in Current Standard of Care
>50%
Incomplete Remission at 1L
Patients fail to achieve remission at 1 year on first-line therapy.
30–40%
Loss of Response
Secondary loss of response forces ongoing therapy cycling.
30–50%
Persistent Symptoms
Ongoing urgency, pain, and fatigue continue despite treatment.
Millions of mild, moderate, and severe IBD patients fail to achieve durable remission. Existing therapies trade efficacy for safety, while failing to address the multiple drivers of persistent inflammation. Even the "safe" oral treatments carry Black Box warnings listing serious infections, malignancies, hepatotoxicity, and cardiovascular risks.
Sources:
US Patient Population: CDC; Lewis et al., Gastroenterology 2023;165(5):1197–1205.
Patient Remission Rate: Jajoo et al., Gastroenterol Hepatol (N Y) 2025;21(12); Le Berre et al., Best Pract Res Clin Gastroenterol 2025; Roblin et al., J Clin Med 2023;12(10):3395.
US Market Sales: FY2025 net sales; bottom up from company FY2025 results (AbbVie, J&J, Takeda) and SEC filings; estimated UC/CD split modeled by FDA approval timing per indication.
Expected Differentiated Profile for Single and Combination IBD Treatment
Convenient and Accessible Oral Tablet
Attractive Safety Profile
Pain and Bowel Urgency Reduction
Preservation of Immune Response
Mucosal Barrier Integrity
Azuriya Pharma welcomes engagement with physicians, investors, and pharma business development partners evaluating the next wave of oral IBD innovation.
More Coming Soon